Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers

Pfizer

Status and phase: Completed; Phase 2

Conditions: Obesity

Treatments: Drug: placebo; Drug: CP-866,087

Study type: Interventional

Funder types: Industry

Identifiers

NCT00479492

A5051019

Details and patient eligibility

About

The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.

Enrollment: 94 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Body Mass Index (BMI) 30 to 40 kg/m2 and total body weight of >110 lbs.
• Otherwise healthy

Exclusion criteria

• Women must be of non-childbearing potential.
• Significant current or history of medical illness.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

94 participants in 4 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: CP-866,087

Drug: CP-866,087

Drug: CP-866,087

2

Experimental group

Treatment:

Drug: CP-866,087

Drug: CP-866,087

Drug: CP-866,087

3

Experimental group

Treatment:

Drug: CP-866,087

Drug: CP-866,087

Drug: CP-866,087

4

Placebo Comparator group

Treatment:

Drug: placebo